Syntara Limited (ASX: SNT)
Sector: Health Care
Market cap: A$36M (as of 2 Nov 2026)
Syntara Limited is a clinical stage drug development company with a focus on blood-related cancers. The company's highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors.
Data as of 2 Nov 2026.
Recent capital raises
Substantial holders — latest moves
| Date | Holder | Move | Holding | Source |
|---|---|---|---|---|
| 28 Aug 2025 | D & A Income, Ltd. | Entry | ?% → 18.23% | Filing ↗ |
| 28 Aug 2025 | D & A Income, Ltd. | Entry | ?% → 18.23% | Filing ↗ |
| 23 June 2025 | BVF Partners L.P. on its own behalf and on behalf of BVF Inc., and Mark N. Lampert | Exit | — | Filing ↗ |
| 26 May 2025 | — | Unknown | — | Filing ↗ |
| 22 May 2025 | Platinum Investment Management Limited | Decrease | 11.7% → 10.8% | Filing ↗ |
Director trades — on-market
Cash and runway
| Metric | Value | As of | Source |
|---|---|---|---|
| Cash | A$14M | 30 Sept 2026 | Filing ↗ |
Ask about SNT in Claude or ChatGPT
Add the Capital Signal connector at https://capitalsignal.io/api/mcp, then ask:
- Has SNT raised money in the last year, and at what discount?
- What was SNT's latest cash position and runway?
Loading SNT…